Crucell Announces Release of 2009 Annual Report and Form 20-F
(Thomson Reuters ONE) -
Leiden, The Netherlands (April 7, 2010) - Dutch biopharmaceutical company
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced
the release of its 2009 Annual Report and Form 20-F.
The full report is available athttp://www.crucell.com
About Crucell
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global
biopharmaceutical company focused on research development, production and
marketing of vaccines, proteins and antibodies that prevent and/or treat
infectious diseases. Its vaccines are sold in public and private markets
worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a
fully-liquid vaccine against five important childhood diseases and a
virosome-adjuvanted vaccine against influenza. Crucell also markets travel
vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine
and the only aluminum-free hepatitis A vaccine on the market. The Company has a
broad development pipeline, with several product candidates based on its unique
PER.C6® production technology. The Company licenses its PER.C6® technology and
other technologies to the biopharmaceutical industry. Important partners and
licensees include Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis,
Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the
Netherlands, with subsidiaries in Argentina, China, Italy, Korea, Spain, Sweden,
Switzerland, UK and the USA. The Company employs over 1200 people. For more
information, please visitwww.crucell.com
Forward-looking statements
This press release contains forward-looking statements that involve inherent
risks and uncertainties. We have identified certain important factors that may
cause actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors please
refer to our Form 20-F, as filed with the US Securities and Exchange Commission
on April 7, 2010, in the section entitled 'Risk Factors'. The Company prepares
its financial statements under International Financial Reporting Standards
(IFRS).
Financial Calendar
11 May 2010 Q1 Results 2010
4 June 2010 Annual General Meeting of Shareholders
17 August 2010 Q2 Results 2010
9 November 2010 Q3 Results 2010
15 February 2011 Q4/FY Results 2010
For further information please contact Crucell:
Oya Yavuz
Vice President Corporate Communications & Investor Relations
Tel. +31 (0)71 519 7064
ir(at)crucell.com
www.crucell.com
[HUG#1401129]
PDF file: http://hugin.info/132631/R/1401129/356201.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.04.2010 - 12:19 Uhr
Sprache: Deutsch
News-ID 1012539
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Leiden
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 60 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crucell Announces Release of 2009 Annual Report and Form 20-F
"
steht unter der journalistisch-redaktionellen Verantwortung von
Crucell N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
